Coverage
12 companies
- Lead links
- 2
- Instruments
- Equity / unspecified
- Sourced relationships
- 12
- Distinct source URLs
- 16
- Crawl status
- Official page mapped
Sourced investor record
Oxford Science Enterprises
Oxford science portfolio source
Portfolio links122 lead relationships
- Indexing state
- Evidence-qualified
- Latest dated link
- 2024-07-01
- Earliest dated link
- 2022-02-01
- Snapshot
- 2026-09-03
Official source
Portfolio located
Open official portfolio ↗Evidence ledger
12 retained relationships
A link records a disclosed or retained research relationship; it does not imply a current holding. Every row exposes the source layer, observation date, match method and publication state. Exact dated matches link onward to the funding record.
Observed roles
Evidence threshold
This page meets the retained indexing threshold through an official portfolio URL, three or more linked companies or two distinct relationship-source URLs.
12 relationships shown
| Company | Role | Round | Date | Named sources | Match / state |
|---|---|---|---|---|---|
| Beacon Therapeutics | participant | Series B | 2024-07-01 | PR Newswire ↗ · Massbio ↗ · Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| PQShield | participant | Series B | 2024-06-01 | Pqshield ↗ · Sifted ↗ · UKTN ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| Sitryx Therapeutics | lead | Series B (described in source as 'additional financing' - letter not explicit) | 2023-09-01 | Svhealthinvestors ↗ · Globenewswire ↗ · Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| OMass Therapeutics | participant | Series B | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ · Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| MiroBio | participant | Series B | 2022-06-01 | Biopharmadive ↗ · Ac ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| First Light Fusion | lead | Series C | 2022-02-14 | Firstlightfusion ↗ · Crunchbase ↗ · Firstlightfusion ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| Genomics plc | participant | Not stated | 2026-09-03 | Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| Grey Wolf Therapeutics | participant | Not stated | 2026-09-03 | Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| ORCA Computing | participant | Not stated | 2026-09-03 | Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| Oxford Quantum Circuits | participant | Not stated | 2026-09-03 | Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| Quantum Motion | participant | Not stated | 2026-09-03 | Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
| Ultromics | participant | Not stated | 2026-09-03 | Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutiondocumented · published |
Recent linked companies
12 of 12 observed companies
The most recently dated retained relationships are shown first; the complete sourced set remains in the ledger above.
Beacon TherapeuticsOpen company recordPQShieldOpen company recordSitryx TherapeuticsOpen company recordOMass TherapeuticsOpen company recordMiroBioOpen company recordFirst Light FusionOpen company recordGenomics plcOpen company recordGrey Wolf TherapeuticsOpen company recordORCA ComputingOpen company recordOxford Quantum CircuitsOpen company recordQuantum MotionOpen company recordUltromicsOpen company record